secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193125-26-051504
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Disc Medicine's bitopertin NDA for EPP; approval delayed
--------------------------------------------------------------------------------

- FDA acknowledged bitopertin significantly lowers PPIX but found insufficient evidence that PPIX change predicts clinical benefit.
- Phase 3 APOLLO study ongoing; topline data expected Q4 2026; could support traditional approval.
- Company plans Type A meeting with FDA; expects resubmission and decision by mid-2027 if APOLLO successful.
- Disc Medicine has approximately $791M cash (unaudited, Dec 31, 2025) with runway into 2029.
- CRL delays potential approval; stock likely to face negative pressure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/0001193125-26-051504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-20260213.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-051504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer